Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide

Critical Care Nursing Quarterly
Michael J SamarinCarrie S Oliphant

Abstract

The development of cardiac arrhythmias in the intensive care unit is common and associated with poor prognoses and outcomes. Because of the complexity of patients admitted to the intensive care unit, the management of arrhythmias is often difficult and may require multiple therapeutic interventions. In order for clinicians to appropriately manage arrhythmias, a thorough understanding of all available therapies, including intravenous antiarrhythmic agents, is essential. Suitable antiarrhythmic agents for use in the critical care setting include amiodarone, lidocaine, and procainamide. While these agents can be effective in managing cardiac arrhythmias, they also possess significant disadvantages and require additional monitoring during use. Therapy with these agents is often complicated because of the presence of significant associated adverse effects, clinician unfamiliarity, variable dosing strategies, and the potential for drug-drug interactions. The purpose of this review is to discuss indications and strategies for safe and effective use of amiodarone, lidocaine, and procainamide.

References

Nov 1, 1977·Clinical Pharmacokinetics·J Koch-Weser
Dec 1, 1977·Kidney International·T P GibsonW A Briggs
Nov 1, 1991·International Journal of Cardiology·B P BajajE J Perrins
Jan 1, 1990·Journal of Toxicology. Clinical Toxicology·A P JonvilleM Breteau
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·M B BacanerR M Brochu
Feb 18, 1989·Lancet·C GarrattA J Camm
Jan 1, 1989·Progress in Cardiovascular Diseases·A Kadish, F Morady
Jul 1, 1986·Clinical Pharmacology and Therapeutics·A W RademakerD G Wyse
Mar 1, 1986·The Journal of Clinical Endocrinology and Metabolism·R H RaoG S Spathis
Mar 1, 1974·American Heart Journal·B N Singh, O Hauswirth
Jan 1, 1974·Annual Review of Medicine·D C Harrison, K A Collinsworth
Dec 1, 1974·Circulation·K A CollinsworthD C Harrison
Jun 1, 1968·Circulation·R R SchumacherJ F Williams
Jan 1, 1984·Annals of the New York Academy of Sciences·E G Giardina
May 1, 1982·Clinical Pharmacokinetics·S J Connolly, R E Kates
Nov 1, 1983·Pacing and Clinical Electrophysiology : PACE·H H RotmenschA M Greenspan
Mar 1, 1984·Clinical Pharmacokinetics·R LatiniR E Kates
Jan 1, 1983·The American Journal of Cardiology·F MoradyL DiCarlo
Jan 1, 1984·International Journal of Cardiology·H M DunnA A Adgey
Apr 1, 1981·Journal of Clinical Pharmacology·E S Waller
May 1, 1995·Annals of Internal Medicine·P J Podrid
May 1, 1993·The Annals of Pharmacotherapy·K K ChitwoodK L Heim-Duthoy
Oct 1, 1996·Journal of Cardiovascular Pharmacology·H R HaF Follath
Aug 15, 1997·Annals of Internal Medicine·A D DesaiR J Sung
Dec 18, 1997·The New England Journal of Medicine·E G DaoudF Morady
Mar 6, 1998·Archives of Internal Medicine·P R Kowey
Sep 16, 1999·The New England Journal of Medicine·P J KudenchukT Walsh
Nov 15, 2001·Pacing and Clinical Electrophysiology : PACE·P SamarendraV Navarro
Mar 22, 2002·The New England Journal of Medicine·Paul DorianAiala Barr
Oct 10, 2002·The American Journal of Cardiology·John C SombergUNKNOWN Amio-Aqueous Investigators
Jan 22, 2003·Journal of the American College of Cardiology·Philippe ChevalierPaul Touboul
Apr 16, 2003·Archives of Internal Medicine·Luz M LetelierGordon H Guyatt
May 28, 2003·International Journal of Cardiology·Ijaz A KhanRamesh M Gowda
Sep 26, 2003·Current Opinion in Critical Care·Hans-Joachim TrappePeter Weismueller
Sep 3, 2004·The American Journal of Cardiology·Milford G WymanJ Michael Criley

❮ Previous
Next ❯

Citations

Aug 2, 2016·Advanced Pharmaceutical Bulletin·Evangelos PolymeropoulosIoannis Τoumpoulis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

© 2021 Meta ULC. All rights reserved